![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Crijns Ineke Straus Sabine Luteijn Michiel
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.35, Iss.1, 2012-01, pp. : 27-32
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Teichert Martina Visser Loes E. Dufour Mark
Drug Safety, Vol. 33, Iss. 4, 2010-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
US FDA strengthens isotretinoin risk management programme
Inpharma, Vol. 1, Iss. 1501, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Bergk Verena Gasse Christiane Schnell Rainer Haefeli Walter
European Journal of Clinical Pharmacology, Vol. 60, Iss. 8, 2004-10 ,pp. :